**TABLE E2.- PATIENT Characteristics- SLIT**

1. **Table E2a. Patient Characteristics- SLIT- Asthma**

| **Study** | **Patients randomized** | **Comparators** | **Age in years****Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease****(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| D'Ambrosio, 1999 1 | 30 | SLITPlacebo | 32 +/- 1732 +/- 18 | 50/5043/57 | 14/016/0 | NR |
| Pajno, 2000 2 | 24 | SLITPlacebo | 11(Range 8-15)12 (Range 8-15) | 58/4250/50 | 12/012/3 | 5 |
| Nelson, 1993 3 | 44 | SLITPlacebo | Range: 20-74; males18-46: femalesRange: 25-48: males19-40: females | 35/6529/71 | 20/221/1 | NR |
| Cortellini 2010 4 | 27 | SLITPlacebo | 19 +/- 7 (Range 16-42)24 +/- 7 (Range 14-44) | 53/4758/42 | 15/012/1 | 4.4 years5.2 years |
| Stelmach, 2009 5Penagos 20086 | 50 | SLITPlacebo | 9 +/- 28 +/- 2 | 60/4070/30 | 25/525/10 | NR |
| Lue, 2006 7 | 20 | SLITPlacebo | 8 +/- 29 +/- 2 | 40/6040/60 | 10/010/0 | 1 |
| Niu, 2006 8 | 110 | SLITPlacebo | 8 +/- 2 (Range 5-11)8+/- 2 (Range 5-12) | 61/3958/42 | 56/754/6 | 1 |
| Sambugaro, 2003 9 | 58 | 8-day induction15-day induction20-day inductionUntreated | 19 (Range 4-43)26 (Range 5-42)17 (Range 6-41)23 (Range 10-37) | 56/4439/6158/4260/40 | 18/018/012/010/0 | NR |

1. **Table E2b. Patient Characteristics- SLIT- Asthma Rhinitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years****Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease****(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Horiguchi, 2007 10 | 67 | SLITPlacebo | 27 +/- 526 +/- 6 | 51/4946/54 | 43/224/2 | 9  |
| Okubo, 200811 | 61 | SLITPlacebo | 41/- 1540+/- 15 | 49/5132/68 | 37/022/02 dropouts before arm allocation | NR |
| Fujimura2011 12 | 103 | SLIT Placebo | 44.4 (Range 16-73)42.3 (Range 19-70) | 34/6622/78 | 51/1537/10 | NR |
| Hordijk, 199813 | 69 | SLITPlacebo | 2828 | 52/4843/57 | 27/830/6Numbers as reported  | NR |
| Tahamiler, 200714 | NR | SLIT /placebo SLIT alone | 28+/- 10 (Range 12-51)26+/- 8 (Range 10-49) | 54/4654/46 | 67/NR70/NR | 2 3  |
| Tseng, 200815 | 63 | SLITPlacebo | 10 +/- 310 +/- 3 | 73/2770/30 | 30/233/2 | 63%: 2-5, 33%: 6-10, 3%: 13 52%:2-5 ,48%: 6-10,0% :13  |
| deBot201116 | 257 | SLIT Placebo | 11.8 +/- 3.111.7 +/- 2.9 | 61/3959/41 | 125/17126/156 withdrew consent before arm allocation | 1. year
 |

**c)Table E2c. Patient Characteristics- SLIT- Asthma Rhinoconjunctivitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years****Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease****(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| D'Ambrosio, 199617 | 40 | SLITPharmacotherapy | 30 (Range 18-41)34 (Range 19-67) | 47/5333/67 | 15/515/5 | 2 or more  |
| la Rosa, 199918Leonardi, 200919 | 41 | SLITPlacebo | 10 (Range 6-14)10 (Range 7-13) | 65/3557/43 | 20/521/4 | 3 4  |
| Bowen, 200420 | 83 | SLITPlacebo | 38 (Range 14-58)35 (Range 16-56) | NRNR | 43/1540/11 | 19 17  |
| Skoner, 201021 | 115 | High dose SLITMedium dose SLITPlacebo | 34 (Range 20-49)34 (Range 19-49)35 (Range 20-50) | 33/6726/7448/53 | 36/539/840/5 | NR |
| Di Rienzo, 200622 | 34 | SLITPlacebo | 34+/- 10 (Range 18-55)Entire Study | 47/53Entire Study | 19/115/1 | NR |
| Makino, 201023 | 25 | SLITPlacebo | 49+/- 1548 +/- 13 | 67/3469/31 | 9/015/1 | 2  |
| Horak, 1998Austria 24 | 41 | SLITPlacebo | 33+/- 15 (Range 18-38)32 +/-16 (Range 18-38) | 36/64(Entire study) | 2021(7 dropouts entire study) | 9 years |
| Lima200225 | 56 | SLITPlacebo | 34 (Range 21-53)34 (Range 21-55) | 54/4732/68 | 28/228/5 | 2  |
| Novembre, 200426 | 113 | SLITControl | 9 (Range 5-14)8 (Range 4-16) | 70/3070/30 | 54/659/10 | NR |
| Ott, 200827Sieber 201228 | 213 | SLIT followed by placeboPlacebo | 33+/- 117.9- 64.734+/- 9Range 7.9- 64.7 | 46/5454/46 | 142/10 67/4  | 13 |
| Panzer, 200829 | 35 | SLITPlacebo-SLIT | 17 +/- 9 (Range 7-50)24 +/- 12 (Range 7-50) | 55/4560/40 | 20/015/0 | NR |
| Roder, 200730 | 204 | SLITPlacebo | 13+/- 7 (Range 7-17)13+/- 3 (Range 6-17) | 67/3344/56 | 108/2696/24 | NR |
| Sabbah, 199431 | 58 | SLITPlacebo | 23 +/- 10 (Range 13-43)27 +/- 12 (Range 13-51) | 59/4148/52 | 29/029/0 | 11 10  |
| Voltolini 2001 32 | 30 | SLITPlacebo | 38 (Range 17-63)39 (Range 24-64) | 47/5327/73 | 15/115/2 | NR |

**d) Table E2d. Patient Characteristics- SLIT- Asthma Asthma and Rhinitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years****Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease****(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Marogna,200533 | 79 | SLITPlacebo | 28 (Range 18-43)29 (Range 19-45) | 55/4557/44 | 39/1040/17 | NR |
| Voltolini, 200934 | 24 | SLITPlacebo | 44+/- 940 +/- 7 | 50/5030/70 | 14/110/1 | NR |
| Marogna201035 | 33 | SLIT Montelukast | NR | NR | 17/116/3 | 2 years |
| Amar, 200936 | 58 | SLIT MonotherapySLIT Multiple allergenPlacebo | 393639 | 26/7441/5947/53 | 19/017/317/2 | 2 years  |
| Marogna, 200937 | 51 | SLITBudesonide | 27 +/- 1 (Range 17-41)27 +/- 1 (Range 19-41) | 44/5646/54 | 25/226/3 | 8 7  |
| Stelmach201138 | 60 | SLIT pre-coseasonal SLIT continuous Placebo  | 8.3Range 5-17 | 65/3574/2661/39 | 20/320/120/2 | 2 years |
| Marogna, 200439 | 511 | SLITControl | 23 (Range 5-60)22 (Range 5-58) | 56/4463/37 | 319/48192/22 | NR |
| Marogna, 200640 | 48 | SLIT - birchSLIT - grassSLIT - birch + grassControl | 28272627 | NRNRNRNR | 12/011/012/013/0 | NR |
| Marogna, 200841 | 216 | SLITControl | 11+/- 010 +/- 0 | 72/3860/40 | 144/1472/6 | 2 years |
| Moreno-Ancillo, 200742 | 105 | SLITPlacebo | 29+/-10 (Range: 14-55)26 +/- 8 (Range: 14-55) | 54/4657/43 | 52/1153/9 | 7  |
| Hirsch, 199743 | 30 | SLITPlacebo | 11 (Range 6-15)10 (Range 6-14) | 67/3467/33 | 15/115/0 | 5 (asthma), 5 (rhinitis)3 (asthma), 3 (rhinitis) |
| O'Hehir, 200944O’Hehir, 200944 | 30 | SLITPlacebo | 29+/- 838+/- 11 | NRNR | 15/215/1 | Minimum 2  |
| Bush201145 | 31 | SLIT high dose SLIT Low dose Placebo | 30.6 | 50/5010/9027/73 | 10/110/311/6 | 2 years |
| Tari, 199046 | 66 | SLITPlacebo | Range 5-12Range 5-12 | Entire study64/36 | 34/432/4 | 3 years |
| Bahceciler, 200147 | 15 | SLITPlacebo |  Median 12 (Range 8-18)Median 12 (Range 7-15) | 50/5058/43 | 8/07/0 | Median 1.5Median 3 |
| Guez, 200048 | 72 | SLITPlacebo | 30+/- 12 (Range 12-51)23 +/- 11 (Range 6-47) | 39/6142/58 | 36/1136/22 | 10 8  |
| Marogna201049 | 78 | SLIT 3 yrsSLIT 4 yrsSLIT 5 yrs | 21.1 +/- 1.4Range 15-34 | NR | 19/521/517/021/9 | 1. years
 |

**e)Table E2e. Patient Characteristics- SLIT- Asthma Asthma and Rhinoconjunctivitis**

| **Study** | **Patients randomized** | **Comparators** | **Age in years****Mean +/- SD (range)** | **Sex % male/female** | **Patients enrolled/ dropouts** | **Duration of Disease****(Mean years affected)** |
| --- | --- | --- | --- | --- | --- | --- |
| Pajno 200350,Pajno 200451 | 30 | SLIT+ fluticasonePlacebo+fluticasone | 11 (Range 8-14)11 (Range 8-14) | 47/5340/60 | 15/115/2 | 5 3  |
| Passalacqua,199952 | 30 | SLITPlacebo | 33 (Range 22-47)30 (Range 19-36) | 67/3433/67 | 15/115/2 | 3 4  |
| Vervloet, 200753 | 76 | SLITPlacebo | 39 (Range 22-60)39 (Range 19-60) | 58/4245/55 | 38/238/4 | 88  |
| Vourdas, 199854 | 69 | SLITPlacebo | 12 (Range 8-17)12 (Range 7-17) | 74/3767/34 | 34/132/13 dropouts before arm allocation | 4 4  |
| Pajno201155 | 80 | SLIT continuous;SLIT co-seasonal  | 11 (Range 8-16)12 (Range 8-16) | 60/4047/53 | 40/340/5 | 5.2 years4.1 years |
| Feliziani, 199556 | 34 | SLITPlacebo | NR | NRNR | 18/016/0 | Minimum 2  |
| Pfaar, 200757 | 185 | SLITPlacebo | 33 (Range 18-59)34 (Range 17-55) | 66/3459/41 | 94/4591/36 | NR |
| Pradalier, 199958 | 126 | SLITPlacebo | 28+/- 11 (Range 8-50)30 +/- 12 (Range 7-58) | 47/5359/41 | 62/361/4 | 9 5  |
| Valovirta, 200659Savolainen, 200660 | 98 | SLIT High doseSLIT Low dosePlacebo | 9 +/- 310 +/- 310 +/- 3 | 49/5261/3962/38 | 32/733/133/6 | 4 5 5  |
| de Blay, 200761 | 118 | SLITPlacebo | 24+/- 7 (Range 12 -41)27 +/- 8 (Range 12 -41) | 56/4461/39 | 61/957/8 | 6 6  |
| Pozzan201062 | 52 | SLIT Placebo | 18 +/- 919+/-10 | 67/3355/45 | 34/118/0 | 2 years |
| Alvarez-Cuesta, 200763 | 50 | SLITPlacebo | 35 (Range 14-55)Entire study | NRNR | 25/825/9 | NRNR |
| Ippoliti, 200364 | 86 | SLITPlacebo | Median;9 (Range 5-12)Median;9 , (Range 7-11) | 60/4156/44 | 47/039/0 | 2 2 |
| Rodriguez, 200665 | 135 | SLITSLIT no 30d updosing | 23+/- 11 (Range 7-55)22 +/- 10 (Range 7-55) | 55/4547/53 | 69/666/6 | NRNR |